Results

Most recent

AMD-Non-Neovascular

1–10 of 101 results for AMD-Non-Neovascular

New Data Analyses on Whether AREDS Patients Should Have Routine Genetic Testing
Stephen R. Kaufman, MD
Annual Meeting Talks
2025
Impact of AREDS Oral Micronutrient Supplementation on Geographic Atrophy Progression: Insights From thePhase 3 OAKS and DERBY Trials
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2025
LIGHTSITE IIIB: A Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy ofPhotobiomodulation in Dry Age-Related Macular Degeneration
David S. Boyer, MD
Annual Meeting Talks
2025
ARCHER II, a Phase 3 Randomized Clinical Trial of ANX007 in Patients With Dry AMD and GA: Study Design andRationale Informed by Outcomes From ARCHER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2025
The 12-Month Safety Results of the PRIMAvera Clinical Trial
Lisa C. Olmos de Koo, MD, MBA
Annual Meeting Talks
2025
Progression of Geographic Atrophy in Patients Receiving Both Anti-VEGF and Pegcetacoplan Injections
Sean David Adrean, MD, FAAO, FASRS
Annual Meeting Talks
2025
Safety Profiles of Combined Anticomplement and Anti-VEGF Intravitreal Therapies for Age-Related MacularDegeneration From Real-World Data
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2025
A Descriptive Analysis of Patients Who Received Pegcetacoplan and Anti-VEGF for the Treatment ofGeographic Atrophy and Neovascular AMD
Nimesh A. Patel, MD
Annual Meeting Talks
2025
Complement Inhibition Treatment for Geographic Atrophy in Eyes With Exudative AMD
Josh Wallsh
Annual Meeting Talks
2025
Clinical Utility of the Fellow Eye in Patients With Bilateral GA Due to AMD: Long-Term Data from thePegcetacoplan Clinical Program
Diana V Do, MD, FASRS
Annual Meeting Talks
2025